• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

喉癌根治性放疗中合并症评分和生活方式因素的影响。

Impact of comorbidity scores and lifestyle factors in curative radiotherapy in laryngeal cancer.

机构信息

Institute of Radiation Oncology, First Faculty of Medicine, Charles University and Bulovka University Hospital, Budinova 67/2, 18081, Prague, Czech Republic.

Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic.

出版信息

Strahlenther Onkol. 2023 Oct;199(10):881-890. doi: 10.1007/s00066-023-02072-y. Epub 2023 Apr 12.

DOI:10.1007/s00066-023-02072-y
PMID:37042973
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10541830/
Abstract

PURPOSE

The principal goal of treatment of laryngeal cancer is to eliminate a tumour while preserving laryngeal function with radio(chemo)therapy being the mainstay of treatment. The aim of this report is to present the influence of comorbidities and lifestyle factors on treatment outcomes in our cohort of patients.

METHODS

During the period 2009-2018, curative radio(chemo)therapy for laryngeal cancer was performed on 189 patients.

RESULTS

The median OS was 50.8 months, with a mean PFS of 96.5 months, mean LC of 101.4 months and a median follow-up of 38.1 months. Acute and late treatment toxicity grade 3-4 was observed in 39.2% patients and 10.1% patients, respectively. A significant effect on overall survival was confirmed for the baseline PS (performance status), severity of weight loss, baseline haemoglobin values, history of alcohol abuse, marital status and comorbidities according to the Charlson Comorbidity Index, as well as the ACE-27 and ASA scores.

CONCLUSIONS

In our cohort of patients treated with radio(chemo)therapy for laryngeal cancer, we found good therapeutic results and an acceptable side-effect profile. Statistically significant predictors of overall survival were the baseline PS, weight loss, anaemia, associated comorbidities, history of alcohol abuse and marital status.

摘要

目的

喉癌治疗的主要目标是在保留喉功能的同时消除肿瘤，放射（化疗）治疗是主要的治疗方法。本报告的目的是介绍合并症和生活方式因素对我们患者队列治疗结果的影响。

方法

在 2009 年至 2018 年期间，对 189 例喉癌患者进行了根治性放射（化疗）治疗。

结果

中位总生存期为 50.8 个月，平均无进展生存期为 96.5 个月，平均局部控制率为 101.4 个月，中位随访时间为 38.1 个月。39.2%的患者出现 3-4 级急性和迟发性治疗毒性，10.1%的患者出现 3-4 级急性和迟发性治疗毒性。根据 Charlson 合并症指数、ACE-27 和 ASA 评分，基线 PS（表现状态）、体重减轻程度、基线血红蛋白值、酒精滥用史、婚姻状况和合并症严重程度对总生存有显著影响。

结论

在我们接受放射（化疗）治疗的喉癌患者队列中，我们发现了良好的治疗效果和可接受的副作用谱。总生存率的统计学显著预测因子是基线 PS、体重减轻、贫血、合并症、酒精滥用史和婚姻状况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea19/10541830/8817c0a52f80/66_2023_2072_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea19/10541830/37d0cc0164c5/66_2023_2072_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea19/10541830/ea5f8811e742/66_2023_2072_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea19/10541830/a92736160a1c/66_2023_2072_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea19/10541830/76681697eb65/66_2023_2072_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea19/10541830/8817c0a52f80/66_2023_2072_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea19/10541830/37d0cc0164c5/66_2023_2072_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea19/10541830/ea5f8811e742/66_2023_2072_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea19/10541830/a92736160a1c/66_2023_2072_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea19/10541830/76681697eb65/66_2023_2072_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea19/10541830/8817c0a52f80/66_2023_2072_Fig5_HTML.jpg

相似文献

1
Impact of comorbidity scores and lifestyle factors in curative radiotherapy in laryngeal cancer.喉癌根治性放疗中合并症评分和生活方式因素的影响。
Strahlenther Onkol. 2023 Oct;199(10):881-890. doi: 10.1007/s00066-023-02072-y. Epub 2023 Apr 12.
2
A single-institutional experience of 15 years of treating T3 laryngeal cancer with primary radiotherapy, with or without chemotherapy.15 年单中心原发性放疗治疗 T3 声门型喉癌（伴或不伴化疗）的经验
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):1000-6. doi: 10.1016/j.ijrobp.2011.07.045. Epub 2011 Nov 16.
3
Severe late dysphagia after multimodal treatment of stage III/IV laryngeal and hypopharyngeal cancer.多模态治疗 III/IV 期喉和声门下咽部癌后严重晚期吞咽困难。
Jpn J Clin Oncol. 2020 Feb 17;50(2):185-192. doi: 10.1093/jjco/hyz158.
4
Comorbidity measurement in patients with laryngeal squamous cell carcinoma.喉鳞状细胞癌患者的共病测量
ORL J Otorhinolaryngol Relat Spec. 2007;69(3):146-52. doi: 10.1159/000099223. Epub 2007 Jan 30.
5
The importance of weight loss during definitive radiotherapy in patients with laryngeal carcinoma.喉癌患者在根治性放疗期间减轻体重的重要性。
J Cancer Res Ther. 2022 Apr-Jun;18(3):638-643. doi: 10.4103/jcrt.JCRT_727_20.
6
What is the price of functional surgical organ preservation in local-regionally advanced supraglottic cancer? Long-term outcome for partial laryngectomy followed by radiotherapy in 32 patients.局部区域晚期声门上癌功能性手术器官保留的代价是什么？32例患者行部分喉切除术后放疗的长期结果。
Tumori. 2013 Nov-Dec;99(6):667-75. doi: 10.1177/030089161309900605.
7
Clinical outcome of elderly patients (≥ 70 years) with esophageal cancer undergoing definitive or neoadjuvant radio(chemo)therapy: a retrospective single center analysis.接受根治性或新辅助放化疗的老年（≥70 岁）食管癌患者的临床结局：回顾性单中心分析。
Radiat Oncol. 2018 May 16;13(1):93. doi: 10.1186/s13014-018-1044-8.
8
[Results of radiotherapy in elderly patients with early laryngeal cancer].老年早期喉癌患者的放射治疗结果
Otolaryngol Pol. 2007;61(4):387-93. doi: 10.1016/S0030-6657(07)70449-3.
9
Subjective voice quality, communicative ability and swallowing after definitive radio(chemo)therapy, laryngectomy plus radio(chemo)therapy, or organ conservation surgery plus radio(chemo)therapy for laryngeal and hypopharyngeal cancer.喉癌和下咽癌接受根治性放（化）疗、喉切除术加放（化）疗或器官保留手术加放（化）疗后的主观嗓音质量、沟通能力和吞咽情况。
J Radiat Res. 2015 Jan;56(1):159-68. doi: 10.1093/jrr/rru093. Epub 2014 Oct 26.
10
Comorbid predictors of poor response to chemoradiotherapy for laryngeal squamous cell carcinoma.喉鳞状细胞癌化放疗反应不良的合并症预测因素。
Laryngoscope. 2012 Mar;122(3):565-71. doi: 10.1002/lary.22489. Epub 2012 Jan 17.

引用本文的文献

1
Mortality risk stratification based on comorbidity status among cervical cancer patients in Lagos, Nigeria.基于尼日利亚拉各斯宫颈癌患者合并症状况的死亡风险分层
Int Health. 2025 Sep 3;17(5):669-677. doi: 10.1093/inthealth/ihaf008.
2
Survival Outcomes in T3 Laryngeal Cancers: Primary Total Laryngectomy vs. Concurrent Chemoradiation or Radiation Therapy-A Meta-Analysis.T3期喉癌的生存结果：原发性全喉切除术与同步放化疗或放射治疗的荟萃分析
Biomedicines. 2023 Jul 28;11(8):2128. doi: 10.3390/biomedicines11082128.
3
The Effect of Xevinapant Combined with Ionizing Radiation on HNSCC and Normal Tissue Cells and the Impact of Xevinapant on Its Targeted Proteins cIAP1 and XIAP.

本文引用的文献

1
Long-term results of radio(chemo)therapy in metastatic carcinoma to cervical lymph nodes from an unknown primary. Adult Comorbidity Evaluation 27 score as a predictor of survival.原发灶不明的转移性颈淋巴结鳞癌同期放化疗的长期结果。成人合并症评估 27 评分作为生存的预测因素。
Strahlenther Onkol. 2023 Feb;199(2):149-159. doi: 10.1007/s00066-022-01983-6. Epub 2022 Aug 9.
2
Tumour volume and radiotherapy prolongation in locally advanced head and neck cancer patients treated with radical IMRT.接受根治性调强放疗的局部晚期头颈癌患者的肿瘤体积与放疗延长情况
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 Dec;166(4):405-411. doi: 10.5507/bp.2021.047. Epub 2021 Aug 24.
3
Xevinapant 联合电离辐射对头颈部鳞状细胞癌和正常组织细胞的影响及其对靶向蛋白 cIAP1 和 XIAP 的影响。
Cells. 2023 Jun 17;12(12):1653. doi: 10.3390/cells12121653.
Determining priority risk groups for compensation of treatment breaks in radical radiotherapy in patients with locally advanced head and neck cancer.
确定局部晚期头颈部癌症患者根治性放疗中治疗中断补偿的优先风险组。
J BUON. 2021 May-Jun;26(3):792-801.
4
Prognostic factors in patients with T1 glottic cancer treated with radiotherapy.声门型 T1 喉癌放疗患者的预后因素。
Strahlenther Onkol. 2019 Sep;195(9):792-804. doi: 10.1007/s00066-019-01481-2. Epub 2019 Jun 18.
5
The Treatment of Laryngeal Cancer.喉癌的治疗
Oral Maxillofac Surg Clin North Am. 2019 Feb;31(1):1-11. doi: 10.1016/j.coms.2018.09.001.
6
Age-adjusted comorbidity and survival in locally advanced laryngeal cancer.年龄调整后的合并症与局部晚期喉癌的生存。
Head Neck. 2018 Sep;40(9):2060-2069. doi: 10.1002/hed.25200. Epub 2018 May 13.
7
Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.喉癌保喉治疗策略的应用：美国临床肿瘤学会临床实践指南更新。
J Clin Oncol. 2018 Apr 10;36(11):1143-1169. doi: 10.1200/JCO.2017.75.7385. Epub 2017 Nov 27.
8
T1-2 glottic cancer treated with radiotherapy and/or surgery.采用放疗和/或手术治疗的T1-2期声门癌。
Strahlenther Onkol. 2017 Dec;193(12):995-1004. doi: 10.1007/s00066-017-1139-4. Epub 2017 May 4.
9
Adding Examples to the ASA-Physical Status Classification Improves Correct Assignment to Patients.在ASA身体状况分类中增加示例可改善对患者的正确分类。
Anesthesiology. 2017 Apr;126(4):614-622. doi: 10.1097/ALN.0000000000001541.
10
An update on larynx cancer.喉癌研究进展。
CA Cancer J Clin. 2017 Jan;67(1):31-50. doi: 10.3322/caac.21386. Epub 2016 Nov 29.